CompletedPhase 3NCT00738062
Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
Studying Dopamine beta-hydroxylase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Chelsea Therapeutics
- Principal Investigator
- Horacio Kaufmann Kaufmann, MDNYU School of Medicine
- Intervention
- Droxidopa(drug)
- Enrollment
- 103 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2008 – 2010
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Dedicated Clinical Research, Litchfield Park, Arizona, United States
- Xenoscience Inc., Phoenix, Arizona, United States
- Sun Health Research Institute, Sun City, Arizona, United States
- The Parkinson's and Movement Disorders Institute, Fountain Valley, California, United States
- Pacific Neuroscience Medical Group, Oxnard, California, United States
- The Parkinson's Institute, Sunnyvale, California, United States
- Electrophysiology Associates, Colorado Springs, Colorado, United States
- Parkinson's Disease & Movment Disorder Center, Boca Raton, Florida, United States
- Southeastern Integrated Medical, Gainesville, Florida, United States
- Mayo Jacksonville Florida Department of Neurology, Jacksonville, Florida, United States
- University of Miami Miller School of Medicine, Miami, Florida, United States
- University of South Florida, Tampa, Florida, United States
- Medical Associates of North Georgia, Canton, Georgia, United States
- Saint Mary of Nazareth Hospital Center, Chicago, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00738062 on ClinicalTrials.gov